title: Response to pemetrexed rechallenge after acquired resistance of ALK inhibitors.
authors.affiliation: Division of Respiratory Medicine, Ryugasaki Saiseikai General Hospital, Nakasato 1-1-1, Ryugasaki, 301-0854 Ibaraki, Japan.
authors.forename: Kunihiko
authors.initials: K
authors.lastname: Miyazaki
authors.affiliation: Division of Respiratory Medicine, Mito Medical Center, University of Tsukuba, Miya-machi 2-3-7, Mito, 310-0015 Ibaraki, Japan. Electronic address: hirosato@md.tsukuba.ac.jp.
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Satoh
authors.affiliation: Division of Respiratory Medicine, Mito Medical Center, University of Tsukuba, Miya-machi 2-3-7, Mito, 310-0015 Ibaraki, Japan.
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Tamura
mesh_terms: D000230:Adenocarcinoma / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D000077192:Adenocarcinoma of Lung; D000328:Adult; D000077548:Anaplastic Lymphoma Kinase; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D000068258:Bevacizumab / Q000008:administration & dosage; D016190:Carboplatin / Q000008:administration & dosage; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D008297:Male; D000068437:Pemetrexed / Q000008:administration & dosage; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000235:genetics*
chemical_list: D000068437:Pemetrexed; D000068258:Bevacizumab; D016190:Carboplatin; C000626173:ALK protein, human; D000077548:Anaplastic Lymphoma Kinase; D020794:Receptor Protein-Tyrosine Kinases